IP Library Granted Patent US 9,074,181
Granted Patent B2
US 9,074,181 · App. 11/917,993 · Granted Jul 7, 2015

Suspension culture of human embryonic stem cells

Inventors: Ramkumar Mandalam (Union City, CA); Yan Li (Menlo Park, CA); Isabelle Nadeau-Demers (San Francisco, CA)
Assignee: Asterias Biotherapeutics, Inc.
C12N5/0606C12N2501/115C12N2501/125C12N2501/15C12N2501/26
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,074,181
App. No.
11/917,993
Granted
Jul 7, 2015
Kind
B2
Abstract

This disclosure provides an improved system for culturing human embryonic stem cells. The cells are cultured in suspension so as to maximize the production capacity of the culture environment. The new culture system of this invention allows for bulk proliferation of hES cells in a more cost-effective manner, which facilitates commercial production of important products for use in human therapy.

Claims (13)

1. A method of culturing undifferentiated hES cells, comprising:

a) suspending human embryonic stem (hES) cells in a nutrient medium;

b) maintaining the hES cells substantially undifferentiated in suspension while culturing;

c) changing the nutrient medium periodically; and

d) optionally splitting the culture from time to time so as to reduce the density of hES cells in the culture;

wherein, the nutrient medium comprises FGF2 and does not comprise added extracellular matrix; and

wherein, the hES cells are not grown on a solid substrate.

2. The method of claim 1 , wherein the concentration of FGF2 in the nutrient medium is at least 40 ng/mL.

3. The method of claim 1 , wherein the concentration of FGF2 in the nutrient medium is about 40 ng/mL.

4. The method of claim 1 , wherein the nutrient medium further comprises at least one of transforming growth factor beta (TGFB), stem cell factor (SCF), and Flt3 ligand (FIt3L).

5. The method of claim 1 , wherein the hES cells are cultured in suspension in nutrient medium comprising FGF2 at a concentration of at least 40 ng/mL for at least two months.

6. The method of claim 1 , further comprising harvesting the cells and plating the harvested cells back onto a solid surface comprising a matrix and continuing to culture the cells in a substantially undifferentiated state.

7. The method of claim 1 , further comprising harvesting the undifferentiated cells from the culture and differentiating the harvested cells.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 11, 2013
From: GERON CORPORATION
To: ASTERIAS BIOTHERAPEUITCS, INC.
Reel/Frame 031578/0054 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 6, 2008
From: MANDALAM, RAMKUMAR; NADEAU-DEMERS, ISABELLE; LI, YAN
To: GERON CORPORATION
Reel/Frame 020608/0105 →
Continuity (2)
Provisional Application 60693266 · Jun 22, 2005
Related Publication 20100144033A1 · Jun 10, 2010